NEW YORK – BioMérieux and BrightInsight have formed a partnership to develop a clinical decision support tool, the firms announced on Wednesday. The partners will bring to market a solution for disease areas across their diagnostic test menu that is compliant with digital health regulations.
Specifically, to help clinicians leverage the insights delivered by high value diagnostics in a timely, optimal manner, BioMérieux said it will launch a digital solution for diagnostics incorporating the BrightInsight Platform and BrightInsight Disease Management Solution.
The technology can be configured to meet regulated digital health "Software as a Medical Device," or SaMD classifications, the firms noted in a statement.
Brian Armstrong, BioMérieux's senior VP of North American clinical operations, said that BrightInsight shares the firm's commitment to advancing public health with innovative, customer-centric solutions. "Our engagement with BrightInsight will enable us to bring our digital health solutions to market faster with the goal of improving patient outcomes," Armstrong said.
Marc Bonnet, senior VP of global health data insights at BioMérieux, said the firm sought a partner with a global footprint and platform to support its global business. "BrightInsight's Disease Management Solution is scalable and configurable to the regulatory, privacy and security requirements of myriad healthcare markets," he said.
BioMérieux's Clinical Digital Solution will launch first in the US, with a subsequent planned global expansion.